Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772929 | 0.93 | FAAH (0.70) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL22769011 | 0.93 | FAAH (0.70) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL24530783 | 0.93 | FAAH (0.70) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL5909190 | 0.91 | FAAH (0.71) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL22280196 | 0.88 | MEN1 (0.52) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL12934925 | 0.85 | FAAH (0.78) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL13373653 | 0.85 | FAAH (0.59) | FAAHMEN1MAPK1KMT2AKDM4E | |
| SCHEMBL12934924 | 0.83 | FAAH (0.83) | FAAHMEN1MAPK1KMT2AHPGD | |
| SCHEMBL12934930 | 0.83 | FAAH (0.83) | FAAHMEN1MAPK1KMT2AHPGD | |
| SCHEMBL12934928 | 0.83 | FAAH (0.83) | FAAHMEN1MAPK1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| WO-2024049769-A2 | PATTERNED RELEASE LAYERS, AND METHODS OF MAKING AND USING THEM IN DEVICE MANUFACTURING | TERECIRCUITS CORPORATION (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230333475-A1 | COMPOSITE MATERIAL COMPRISING A RELEASE MATERIAL AND A THERMOPOLYMER MATERIAL, AND USES THEREOF | TERECIRCUITS CORPORATION | 2023-10-19 | — | — | US | disclosed |
| US-20230333475-A1 | COMPOSITE MATERIAL COMPRISING A RELEASE MATERIAL AND A THERMOPOLYMER MATERIAL, AND USES THEREOF | TERECIRCUITS CORPORATION | 2023-10-19 | — | — | US | disclosed |
| WO-2023200975-A1 | COMPOSITE MATERIAL COMPRISING A RELEASE MATERIAL AND A THERMOPOLYMER MATERIAL, AND USES THEREOF | TERECIRCUITS CORPORATION (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20230130004-A1 | RELEASE LAYER COMPOSITION FOR TRANSFER OF COMPONENTS | TERECIRCUITS CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230130004-A1 | RELEASE LAYER COMPOSITION FOR TRANSFER OF COMPONENTS | TERECIRCUITS CORPORATION | 2023-04-27 | — | — | US | disclosed |
| WO-2023023554-A1 | RELEASE LAYER COMPOSITION FOR TRANSFER OF COMPONENTS | TERECIRCUITS CORPORATION (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | FAAH 1857/4885MEN1 3475/4885MAPK1 1890/4885 |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | MMP1, PIK3CA, AKT2 | FAAH 4065/4885MEN1 3624/4885MAPK1 199/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | FAAH 828/4885MEN1 2971/4885MAPK1 1961/4885 |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | FAAH 3897/4885MEN1 1278/4885MAPK1 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.